MDL

Philips delivers strong sales growth, profitability and cash flow; raises full-year outlook

Retrieved on: 
Monday, October 23, 2023

Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, mainly driven by increased sales, pricing and productivity measures.

Key Points: 
  • Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, mainly driven by increased sales, pricing and productivity measures.
  • Comparable order intake (the order book covers around 40% of Group sales) was 9% lower than in Q3 2022.
  • Connected Care comparable sales increased 10% in the quarter, with double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics.
  • Philips launched its ambulatory monitoring offering in Japan, combining Philips ePatch Holter monitors with ECG analysis through AI and advanced algorithms.

Purdue Research Foundation Terminates Medallion’s License to Use Lad Chromatography

Retrieved on: 
Wednesday, October 18, 2023

VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that its license to use ligand assisted displacement chromatography has terminated.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that its license to use ligand assisted displacement chromatography has terminated.
  • The Medallion Board and management will consider next steps in light of this development.
  • Separately, Douglas Newby has given notice of his resignation as Chief Financial Officer but has agreed to continue to serve for up to 30 days on an interim basis pending appointment of a new CFO.
  • Rod McKeen, Chairman, thanked Mr. Newby for all his efforts and hard work including working closely with the technical team that sought to achieve the technical and financial milestones under the Purdue technology license.

Possible Third J&J Bankruptcy Attempt Amplifies Concerns over Corporate Abuse of Courts

Retrieved on: 
Tuesday, October 24, 2023

"J&J's corporate leadership seems determined to keep pushing this strategy, and as advocates for these women we will continue to push back."

Key Points: 
  • "J&J's corporate leadership seems determined to keep pushing this strategy, and as advocates for these women we will continue to push back."
  • During the past year, the U.S. Bankruptcy Court in New Jersey and the Third U.S.
  • Circuit Court of Appeals has ruled J&J's ploy does not meet the standards for a good faith bankruptcy, in large part because the multibillion-dollar company is not in "financial distress."
  • Attorneys for the plaintiffs believe that under bankruptcy laws those victims would receive far less compensation than through civil trials or settlement negotiations outside of the bankruptcy system.

FaceTec® Exceeds Two Billion 3D Liveness Checks Annual Rate as Hypergrowth Continues in Q3 2023

Retrieved on: 
Thursday, October 19, 2023

SUMMERLIN, Nev., Oct. 19, 2023 /PRNewswire-PRWeb/ -- FaceTec, Inc. has announced its exceptional growth continued in Q3 2023. With its position as the global standard for 3D Face Verification firmly in place, it is now expanding into the Know Your Customer (KYC) sector. New independent test results show that FaceTec's powerful 3D Liveness, Photo ID Scan, and 3D:2D Face Matching software consistently outperforms legacy 2D competition.

Key Points: 
  • New independent test results show that FaceTec's powerful 3D Liveness, Photo ID Scan, and 3D:2D Face Matching software consistently outperforms legacy 2D competition.
  • FaceTec now performs 2 billion+ 3D Liveness Checks, annualized (5m+/day)
    FaceTec signed 11 new commercial agreements directly and added over 10 new customers through partners in LATAM alone.
  • The PAD testing was performed in conjunction with 1,000+ live-user, real-world "demographically diverse" 3D Liveness Checks plus ID Scans with 3D:2D Face Matching.
  • FaceTec only charges for 3D Liveness Checks performed by end-users; nothing else.

Medallion Receives Notice of Default From Purdue Research Foundation

Retrieved on: 
Tuesday, October 10, 2023

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that it has received notice of default from Purdue Research Foundation (“PRF”) and has until October 17, 2023 to cure the default or the Company’s license to use ligand assisted displacement chromatography will be terminated.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that it has received notice of default from Purdue Research Foundation (“PRF”) and has until October 17, 2023 to cure the default or the Company’s license to use ligand assisted displacement chromatography will be terminated.
  • The Company is in discussion with PRF about curing the default or extending the term but there is no assurance that those discussions will be successful.

Bloomberg Law Report Provides Actionable Insights on the Multidistrict Litigation Process

Retrieved on: 
Thursday, October 12, 2023

ARLINGTON, Va., Oct. 12, 2023 /PRNewswire/ -- Bloomberg Law today announced the release of a new Multidistrict Litigation report that provides statistical evaluations of MDL court activity and data-driven analysis of the MDL process itself.

Key Points: 
  • ARLINGTON, Va., Oct. 12, 2023 /PRNewswire/ -- Bloomberg Law today announced the release of a new Multidistrict Litigation report that provides statistical evaluations of MDL court activity and data-driven analysis of the MDL process itself.
  • More than one million lawsuits have been officially consolidated into MDL cases over the years, but only about 1% of consolidated cases make it to trial.
  • While infrequent, the largest MDLs can result in multi-billion-dollar settlements, significant impact to corporate valuations, and hundreds of millions of dollars in legal fees.
  • With more than a dozen charts and tables—along with case studies, judicial profiles, and analysis—this report contains crucial information to help lawyers navigate MDL and use the process to their advantage.

Lanier Law Firm's Rebecca Phillips Named to Leadership Post in Bard PowerPort MDL

Retrieved on: 
Tuesday, October 3, 2023

HOUSTON, Oct. 3, 2023 /PRNewswire/ -- Rebecca Phillips of The Lanier Law Firm has been appointed among three co-lead counsels for plaintiffs in the multidistrict litigation alleging complications and injuries from Bard PowerPort implantable catheter devices.

Key Points: 
  • HOUSTON, Oct. 3, 2023 /PRNewswire/ -- Rebecca Phillips of The Lanier Law Firm has been appointed among three co-lead counsels for plaintiffs in the multidistrict litigation alleging complications and injuries from Bard PowerPort implantable catheter devices.
  • The Bard devices are designed to provide intravenous delivery of fluids or medicine and was initially approved by the U.S. Food and Drug Administration in 2000.
  • In March 2020, the FDA posted a recall notice for several Bard PowerPort models due to increased device failure rates.
  • The case is IN RE: Bard Implanted Port Catheter Product Liability Litigation, MDL 3081, in U.S. District Court for the District of Arizona.

BERGER MONTAGUE SHAREHOLDER SHANON J. CARSON AND SENIOR COUNSEL JENNIFER P. ELWELL APPOINTED TO LEADERSHIP POSITIONS IN THE BARD IMPLANTED PORT CATHETER MDL LITIGATION

Retrieved on: 
Tuesday, September 26, 2023

The court appointed Mr. Carson to the Plaintiffs' Executive Committee and Ms. Elwell to the Plaintiffs' Steering Committee.

Key Points: 
  • The court appointed Mr. Carson to the Plaintiffs' Executive Committee and Ms. Elwell to the Plaintiffs' Steering Committee.
  • Berger Montague has been contacted by hundreds of individuals alleging injuries by Bard port catheters.
  • Bard port catheters are surgically placed under the skin, typically in the chest, and consist of an injection port and a catheter.
  • Please direct all inquiries to Berger Montague's Bard Port Catheter Litigation Team by email to [email protected] or by telephone at (215) 875-3072.

The Village of Farmingdale Benefits from the 3M and DuPont, Chemours and Corteva Landmark Settlements in the AFFF MDL

Retrieved on: 
Thursday, September 14, 2023

The Village of Farmingdale is pleased to announce its satisfaction with the groundbreaking settlements reached in the Aqueous Film-Forming Foam (AFFF) Multi-District Litigation (MDL) involving 3M, DuPont, Chemours, and Corteva.

Key Points: 
  • The Village of Farmingdale is pleased to announce its satisfaction with the groundbreaking settlements reached in the Aqueous Film-Forming Foam (AFFF) Multi-District Litigation (MDL) involving 3M, DuPont, Chemours, and Corteva.
  • As per the Estimated Allocation Range Tables provided by the PFAS Settlement Steering Committee, the Village of Farmingdale anticipates receiving substantial compensation from these settlements.
  • Initial settlement amounts are anticipated to provide the Village of Farmingdale of up to $5,000,000.00 from DuPont, Chemours and Corteva and 3M.
  • Notably, there are 15 defendants remaining in additional litigation and the Village is working to secure additional settlements from those defendants.

Lex Machina Releases 2023 Product Liability Litigation Report

Retrieved on: 
Thursday, September 14, 2023

MENLO PARK, Calif., Sept. 14, 2023 /PRNewswire/ -- Lex Machina, a LexisNexis company, today releases its annual Product Liability Litigation Report. The report examines trends in product liability litigation in federal district courts and appellate courts. Focusing on the five-year period from 2018 to 2022, it surveys emerging trends in case filings, venues, judges, law firms, parties, timing metrics, case resolutions, findings, and damages. The report often focuses on different sets of data, e.g., filtering cases in order to provide analytics on general product liability cases, medical device/pharmaceutical cases, vehicle cases, and federal appellate product liability cases.

Key Points: 
  • Product liability cases (excluding MDL Associated Cases) have generally increased over recent years, with subsets of cases clustered around specific large-scale litigation events
    MENLO PARK, Calif., Sept. 14, 2023 /PRNewswire/ -- Lex Machina, a LexisNexis company, today releases its annual Product Liability Litigation Report.
  • The report examines trends in product liability litigation in federal district courts and appellate courts.
  • The report often focuses on different sets of data, e.g., filtering cases in order to provide analytics on general product liability cases, medical device/pharmaceutical cases, vehicle cases, and federal appellate product liability cases.
  • "Lex Machina monitors different trends in product liability litigation through analyzing the kinds of data offered in this report," said Ron Porter, Lex Machina's product liability legal data expert and editor of the report.